<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971994</url>
  </required_header>
  <id_info>
    <org_study_id>2018/113</org_study_id>
    <secondary_id>2018-A02945-50</secondary_id>
    <nct_id>NCT03971994</nct_id>
  </id_info>
  <brief_title>Emotion and Attention in Alzheimer's Disease (ATEMMA)</brief_title>
  <acronym>ATEMMA</acronym>
  <official_title>Attentional Capture by Emotional Information in Alzheimer's Disease : an fMRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the existence of emotional attention&#xD;
      impairments in Alzheimer's Disease, in correlation with amygdala and attention networks&#xD;
      alterations. To this end, functional and structural neuroimaging will be used. A face&#xD;
      expression recognition task, along with eyetracking, will be used to assess emotional&#xD;
      attention impairments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2019</start_date>
  <completion_date type="Actual">November 30, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Classic recognition score</measure>
    <time_frame>1 hour</time_frame>
    <description>Facial expression recognition score (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Classic fixation time faces</measure>
    <time_frame>1 hour</time_frame>
    <description>Fixation time on eyes as measured with eyetracking (ms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fixation time scenes</measure>
    <time_frame>30 mn</time_frame>
    <description>Fixation time on emotional scenes outside of MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Classic fMRI activity</measure>
    <time_frame>2 hours</time_frame>
    <description>fMRI activity in amygdala and emotional attention networks during face exploration and resting-state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alternative recognition score</measure>
    <time_frame>1 hour</time_frame>
    <description>Facial expression recognition score (%) during an alternative task designed to encourage focus on the eyes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alternative fixation time faces</measure>
    <time_frame>1 hour</time_frame>
    <description>Fixation time on eyes as measured with eyetracking (ms) during this alternative task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alternative fMRI activity</measure>
    <time_frame>2 hours</time_frame>
    <description>fMRI activity in amygdala and emotional attention networks during this alternative task</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Young adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants aged between 18 and 40 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy old adults</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants aged between 65 and 95 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Alzheimer's Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged between 65 and 95 years old with a diagnosis of Alzheimer's Disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Facial expression recognition task</intervention_name>
    <description>We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.</description>
    <arm_group_label>Healthy old adults</arm_group_label>
    <arm_group_label>Patients with Alzheimer's Disease</arm_group_label>
    <arm_group_label>Young adults</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers :&#xD;
&#xD;
               -  Affiliation to social security&#xD;
&#xD;
               -  Medical examination before study participation&#xD;
&#xD;
               -  No contraindication to MRI&#xD;
&#xD;
               -  Informed consent signed&#xD;
&#xD;
               -  Young adults older than 18 years and younger than 40 years&#xD;
&#xD;
               -  Healthy old adults older than 65 years and younger than 95 years&#xD;
&#xD;
               -  Visual acuity allowing normal perception of stimuli or corrected to normal vision&#xD;
&#xD;
          -  Patients with Alzheimer's Disease :&#xD;
&#xD;
               -  Affiliation to social security&#xD;
&#xD;
               -  Medical examination before study participation&#xD;
&#xD;
               -  No contraindication to MRI&#xD;
&#xD;
               -  Informed consent signed&#xD;
&#xD;
               -  Patients with Alzheimer's Disease at mild or moderate stage (National Institute&#xD;
                  on Aging and Alzheimer's Association criteria), diagnosed at Grenoble CMRR&#xD;
                  (Centre Mémoire de Ressources et de Recherche)&#xD;
&#xD;
               -  Patients older than 65 years and younger than 95 years&#xD;
&#xD;
               -  MMSE (Mini-Mental State Examination) &gt; 18/30&#xD;
&#xD;
               -  Ability to understand study instructions and give an informed consent&#xD;
&#xD;
               -  Visual acuity allowing normal perception of stimuli or corrected to normal vision&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Every participant having a vascular stent implanted less than 6 weeks before study&#xD;
&#xD;
          -  Every participant having a biomedical material implanted that is considered &quot;unsafe&quot;&#xD;
             in the list: http://www.mrisafety.com/TheList_search.asp&#xD;
&#xD;
          -  Every acquisition procedure not respecting required conditions by the &quot;conditional&quot;&#xD;
             usage in a participant having a biomedical material implanted that is considered&#xD;
             &quot;conditional&quot; in the list: http://www.mrisafety.com/TheList_search.asp&#xD;
&#xD;
          -  Every subject having a biomedical material such as a cardiac, neuronal or sensorial&#xD;
             stimulator (cochlear implant because of demagnetization, electrode heating or artefact&#xD;
             risk) or a ventricular drain without trained medical or paramedical support during MRI&#xD;
             for these participants&#xD;
&#xD;
          -  Ferromagnetic object inside the eye or the skull, close to nervous structures&#xD;
             (displacement and complications risk such as eye or brain damage)&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Psychiatric (e.g., bipolar disorder) or neurological pathology (e.g., epilepsy,&#xD;
             Parkinson's Disease) other than Alzheimer's Disease&#xD;
&#xD;
          -  Non cooperating participant&#xD;
&#xD;
          -  Severe and uncontrolled affection: cardiac, respiratory, haematological, renal,&#xD;
             hepatic, cancerous&#xD;
&#xD;
          -  Participation to other research protocols with exclusion period or MRI during the past&#xD;
             weel&#xD;
&#xD;
          -  Drug therapy likely to modulate brain activity : neuroleptics, lithium, etc...&#xD;
&#xD;
          -  Alcohol ingestion before study&#xD;
&#xD;
          -  Participants concerned by articles L1125-5 to L1121-8 of CSP (Code de la Santé&#xD;
             Publique) (pregnant or nursing women, underage or protected adult, person under&#xD;
             administrative or judicial oversight&#xD;
&#xD;
          -  Participant receiving more than 4500 euros for his participation to other studies&#xD;
             involving human person during the past 12 months before this study&#xD;
&#xD;
          -  Participant unable to be contacted in case of emergency&#xD;
&#xD;
          -  Inability to understand study instructions or give an informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>January 14, 2022</last_update_submitted>
  <last_update_submitted_qc>January 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>attention</keyword>
  <keyword>emotion</keyword>
  <keyword>eye movements</keyword>
  <keyword>amygdala</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

